Global Cellular Immunotherapy Market Size study, byTherapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By End-us

Global Cellular Immunotherapy Market Size study, byTherapy Type (CAR T Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By End-use (Hospitals, Cancer Institutes,Others) and Regional Forecasts 2022-2028

Global Cellular Immunotherapy Market is valued at approximately XX in 2021 and is anticipated to grow with a healthy growth rate of more than xx% over the forecast period 2022-2028.Cellular immunotherapy, also known as adoptive cell therapy, is a type of cancer treatment that employs immune system cells.The development of advanced cell-based therapies, the rising prevalence of cancer, and increased R&D investment by key companies are some of the major factors driving market growth. Furthermore, the increasing number of product approvals and growing adoption of these therapies for cancer treatment is driving market growth.According to Globocan estimates, an estimated 19.2 million new cancer cases were reported worldwide in 2020, with this figure expected to rise to 24.5 million by 2030. Cancer is expected to kill 10 million people by 2020. According to Cancer Research UK, over 375,000 new cancer cases are reported in the United Kingdom each year. Furthermore, according to WHO estimates, two-thirds of the world's population aged 60 and up lives in developing countries. The most common factor that increases the risk of cancer is ageing. As a result, the rising geriatric population is expected to increase in prevalence over the forecast period, driving demand for cellular immunotherapies.However, the high cost of manufacturing cellular immunotherapy products is expected to limit growth.

The key regions considered for the global Cellular Immunotherapy marketstudy includeAsia Pacific, North America, Europe, Latin America, and Rest of the World.The Asia Pacific region is predicted to grow at the fastest rate due to unexplored prospects and increased awareness about cellular immunotherapy, as well as quickly building healthcare infrastructure. Because of its well-established healthcare infrastructure, availability of advanced therapies, high disposable income, and high per capita healthcare expenditure, North America dominated the market in terms of revenue in 2021.

Major market players included in this report are:
Bristol-Myers Squibb Company
Novartis AG
Gilead Sciences Inc. (Kite Pharma)
F. Hoffmann-La Roche Ltd
Merck KGaA
GlaxoSmithKline plc.
AstraZeneca
Pfizer Inc.
Johnson & Johnson
Celyad
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
ByTherapy Type:
CAR T Cell Therapy
Dendritic Cell Therapy
NK Cell Therapy
TIL Therapy
Others

ByIndication:
B-cell Malignancies
Prostate Cancer
Liver Cancer
Renal Cell Carcinoma
Others
ByEnd-use:
Hospitals
Cancer Institutes
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Cellular Immunotherapy Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Bristol-Myers Squibb Company
Novartis AG
Gilead Sciences Inc. (Kite Pharma)
F. Hoffmann-La Roche Ltd
Merck KGaA
GlaxoSmithKline plc.
AstraZeneca
Pfizer Inc.
Johnson & Johnson
Celyad

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.